Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01145755 · ClinicalTrials.gov registry record · Phase 2
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT01145755 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 131 participants.
The verdict
NCT01145755, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG AZD2066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01145755
The ClinicalTrials.gov registry entry for NCT01145755 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01145755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01145755 about?
NCT01145755 is a clinical study titled "6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder". This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
What is the current status of trial NCT01145755?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01145755?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), AZD2066 (DRUG).
Who is sponsoring clinical trial NCT01145755?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.